Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Harvard Business School
Express Scripts
Moodys
Merck

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Patent: 7,198,789

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 7,198,789
Title:Methods and compositions for modulating interleukin-21 receptor activity
Abstract: Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor (\"IL-21R\" or \"MU-1\"), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.
Inventor(s): Carter; Laura (Medford, MA), Carreno; Beatriz (Acton, MA), Lowe; Leslie D. (Sudbury, MA), Whitters; Matthew J. (Hudson, MA), Dunussi; Kyri (Belmont, MA), Collins; Mary (Natick, MA), Ma; Margery (W. Roxbury, MA), Young; Deborah A. (Melrose, MA), Witek; JoAnn S. (Acton, MA), Larsen; Glenn (Sudbury, MA), Kasaian; Marion T. (Charlestown, MA), Donaldson; Debra D. (Medford, MA), Unger; Michelle (Chapel Hill, NC)
Assignee: Genetics Institute, LLC (Cambridge, MA)
Application Number:10/264,634
Patent Claims:see list of patent claims

Details for Patent 7,198,789

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Genetics Institute, LLC (Cambridge, MA) 2018-03-17 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Genetics Institute, LLC (Cambridge, MA) 2018-03-17 RX Orphan search
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31   Start Trial Genetics Institute, LLC (Cambridge, MA) 2018-03-17 RX Orphan search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31   Start Trial Genetics Institute, LLC (Cambridge, MA) 2018-03-17 RX Orphan search
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 003 2001-11-14   Start Trial Genetics Institute, LLC (Cambridge, MA) 2018-03-17 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 7,198,789

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
Moodys
Baxter
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.